Belite Bio, Inc, ADR (BLTE) PT Raised to $187 at Benchmark on Positive Phase 3 Dragon Trial Results
Tweet Send to a Friend
Benchmark analyst Bruce D. Jackson raised the price target on Belite Bio, Inc, ADR (NASDAQ: BLTE) to $187.00 (from $132.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
